ThromboGenics NV (Euronext Brussels: THR) is a leading biopharmaceutical company focused on the discovery and development of novel therapeutics in a number of important diseases related to the back of the eye, bloodvessels and cancer.

The Company's goals is to show efficacy and to demonstrate safety for its products by taking them through to completion of mid-to late stage clinical development. To leverage its expertise, ThromboGenics selectively forms development and marketing collaborations with experienced partners in the pharmaceutical industry. Such collaborations can lead to ThromboGenics generating revenues via milestone payments, as well as royalties on commercial sales.

ThromboGenics was founded by its Chairman, Professor Désiré Collen, a renowned expert in cardiovascular disease. The Company currently has around 50 people based at its headquarters in Leuven, Belgium, and at its facilities in Ireland and the U.S.